GeoVax Labs, Inc. 8K

GeoVax Labs, Inc. reported Q2 2026 results, discontinued active development of its GEO-CM04S1 COVID-19 vaccine, and shifted resources to its GEO-MVA orthopoxvirus vaccine and Gedeptin immuno-oncology programs while preparing a pivotal GEO-MVA study under an expedited regulatory pathway.

GeoVax Labs, Inc. reported its financial results for the quarter and six months ended June 30, 2026, highlighting a reduced quarterly net loss of approximately $4.4 million versus $5.4 million in the prior year period, with lower R&D and G&A expenses largely due to the wind-down of its BARDA-funded GEO-CM04S1 COVID-19 vaccine program and a strategic reprioritization of its portfolio. In May 2026, the company formally discontinued active development of GEO-CM04S1, citing contraction of the COVID-19 vaccine market and a shift of resources toward its lead GEO-MVA orthopoxvirus vaccine and Gedeptin immuno-oncology programs, while maintaining that the decision was not based on safety or efficacy concerns. Operationally, GeoVax advanced clinical and manufacturing readiness for a pivotal GEO-MVA immunobridging study expected to initiate in the fourth quarter of 2026 under an expedited EMA-supported regulatory pathway, continued development of its AGE1 continuous cell-line manufacturing platform, and pursued positioning of Gedeptin for combination strategies with PD-1 checkpoint inhibitors. The company ended the quarter with approximately $3.1 million in cash, essentially flat with year-end 2025, as it emphasized disciplined capital allocation and pursuit of future government and international procurement opportunities to support its lead programs.

Filing Facts

CIK

832489

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-024522

Alert Tier

7